Seller: Vineet D. Menachery
Contact Seller / Seller’s Other Items / Save This Seller
Condition: toxic
Time Left: 11 days, 3 hours
Bids: [28] Bidder List
Current Bid: $1,450,000,000
Location: Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Shipping: Buyer responsible for securing Infectious Substance Special Permits from US and foreign agencies as required. Laboratory materials will only be released to be preapproved DOT-SP 16279 companies.
Whether you are planning a false flag operation, working on global population reduction, or selling billions of doses of untested vaccines under emergency approval, this enhanced COVID genome will provide everything you need.
The COVID-22 virus has the following benefits:
Documentation includes complete genetic sequencing with enhanced receptor binding domains (RBD) and maximized up receptors via enhancements to spike proteins K417N and N501Y, full documentation of all non-structural protein modifications and amino acid inserts, and nucleocapsid modifications for increased resistance to antigenetic agents.
Live virus samples will be delivered separately from the data.
USBWL
Pfizer
J&J
AstroZenaca
CIA
USBWL
Pfizer
MOSSAD
MI-6
Moderna
BioNTech
USBWL
Merck & Co.
MI-6
MOSSAD
CIA
USBWL
Novavax
Merck & Co.
Gilead Sciences
MOSSAD
Sinovac
IIBR
Merck & Co.
Inovio
Evvivax
Pfizer
CIA
Opening Bid
$1,450,000,000
$1,400,000,000
$1,350,000,000
$1,300,000,000
$1,250,000,000
$1,200,000,000
$1,150,000,000
$1,100,000,000
$1,050,000,000
$1,000,000,000
$950,000,000
$900,000,000
$850,000,000
$800,000,000
$750,000,000
$700,000,000
$650,000,000
$600,000,000
$550,000,000
$500,000,000
$450,000,000
$400,000,000
$350,000,000
$300,000,000
$250,000,000
$200,000,000
$150,000,000
$100,000,000
$100,000,000
